All In Biotech

Drug Trial Radar · NCT06280209

A Phase 1/2 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMN 351 in Participants With Duchenne Muscular Dystrophy

A Phase 1/2, Open-Label, Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Intravenous Doses of BMN 351 in Participants With Duchenne Muscular Dystrophy

Last checked: Nov 19, 2026Latest source record: Jun 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

18

Actual

Start

Jan 3, 2024

Primary completion

Apr 14, 2027

Study completion Apr 14, 2027

Sponsor

Lead sponsor
BioMarin PharmaceuticalBioMarin (BMRN)
Sponsor type
Industry
First posted
Feb 28, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Male only, from 4 years, up to 10 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to test the safety and tolerability of BMN 351 in participants with Duchenne Muscular Dystrophy (DMD) with a genetic mutation amenable to exon 51 skipping.

Conditions

  • Duchenne Muscular Dystrophy

Interventions

  • BMN 351Drug

    Anti-sense Oligonucleotide BMN 351 will be administered intravenously.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To evaluate and safety and tolerability of single and multiple doses of BMN 351 (incidence, severity, and dose-relationship of adverse effects and changes in laboratory parameters).Time frame: Up to 97 weeks.

Locations

7 sites in 5 countries. Site status is shown where the registry gives one.

  • Fondazione Serena ETS - Centro Clinico NeMO Milano

    Milan, Italy

  • UOC Fase I - Fondazione Policlinico Universitario A. Gemelli IRCCS - Universita Cattolica del Sacro Cuore

    Rome, Italy

  • Leids Universitair Medisch Centrum

    Leiden, Netherlands

  • Hospital Sant Joan de Deu

    Barcelona, Spain

  • Hospital Viamed Santa Angela De la Cruz

    Seville, Spain

  • Yeditepe University Kosuyolu Hospital

    Istanbul, Turkey (Türkiye)

  • Great Ormond Street Hospital NHS Foundation Trust

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.